andrewkaretas, Author at Allogene - Page 3 of 16

4: Statement of changes in beneficial ownership of securities

Post author:andrewkaretas
Post published:December 10, 2024
Post category:SEC Filings

Allogene Therapeutics, Inc.

Continue Reading

4: Statement of changes in beneficial ownership of securities

Post author:andrewkaretas
Post published:December 9, 2024
Post category:SEC Filings

Allogene Therapeutics, Inc.

Continue Reading

144: Filed by “insiders” prior intended sale of restricted stock. Non-EDGAR filing

Post author:andrewkaretas
Post published:December 9, 2024
Post category:SEC Filings

Allogene Therapeutics, Inc.

Continue Reading

Read more about the article Alpha3: A Pivotal Phase 2 Study of First-Line Consolidation With Cemacabtagene Ansegedleucel (Cema‑Cel) in Patients With Large B‑Cell Lymphoma and Minimal Residual Disease After Response to Standard Therapy

Alpha3: A Pivotal Phase 2 Study of First-Line Consolidation With Cemacabtagene Ansegedleucel (Cema‑Cel) in Patients With Large B‑Cell Lymphoma and Minimal Residual Disease After Response to Standard Therapy

Post author:andrewkaretas
Post published:December 9, 2024
Post category:CD19 Scientific Publications

Continue Reading

144/A: Amendment to a previously filed 144

Post author:andrewkaretas
Post published:December 4, 2024
Post category:SEC Filings

Allogene Therapeutics, Inc.

Continue Reading

144: Filed by “insiders” prior intended sale of restricted stock. Non-EDGAR filing

Post author:andrewkaretas
Post published:December 2, 2024
Post category:SEC Filings

Allogene Therapeutics, Inc.

Continue Reading

December 2, 2024 11:00 AM EST : The Citizens JMP Hematology and Oncology Summit

Post author:andrewkaretas
Post published:November 27, 2024
Post category:Events

Continue Reading

December 3, 2024 8:00 AM EST : Piper Sandler 36th Annual Healthcare Conference

Post author:andrewkaretas
Post published:November 27, 2024
Post category:Events

Continue Reading

November 20, 2024 6:30 AM EST : Jefferies London Healthcare Conference

Post author:andrewkaretas
Post published:November 20, 2024
Post category:Events

Continue Reading

Allogene Therapeutics Announces Participation in December Investor Conferences

Post author:andrewkaretas
Post published:November 19, 2024
Post category:Latest News

SOUTH SAN FRANCISCO, Calif. , Nov. 19, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products…

Continue Reading